Guides

Retatrutide

Investigational. Not FDA approved; available legally only in Lilly clinical trials.

• Retatrutide dosage chart: the published trial schedules Dosage charts

  Retatrutide dose schedules from Phase 3 TRIUMPH and Phase 2 trials: 2 mg start, steps every 4 weeks to 4, 9 or 12 mg, with dates and per-arm results.

• Retatrutide half-life: how long it stays in the body Pharmacokinetics

  Retatrutide's half-life is about 6 days. Elimination math, time to steady state, the 1.8 weekly accumulation ratio and washout after 2 to 8 weeks.

• Retatrutide reconstitution chart: vial size × water volume → units Reconstitution charts

  Lab arithmetic for retatrutide research vials: mg/mL concentration and U-100 unit readings for 5 to 60 mg vials with 1, 2 or 3 mL of water.

• Is retatrutide FDA approved? Status as of October 2026 Regulatory status

  Retatrutide (nicknamed GLP-3) is not FDA approved as of Oct 19, 2026. Dated timeline of trials, FDA warning letters, registry status and the planned 2027 BLA.

• Retatrutide side effects: trial rates by dose Side effects

  Retatrutide side effects by dose from TRIUMPH-1 to -4, TRANSCEND-T2D-1 and Phase 2: nausea, dysesthesia, discontinuations, and what is not yet published.

• Retatrutide results: TRIUMPH-1, -2, -3 and the other Phase 3 trials Trial results

  Retatrutide trial results by dose for TRIUMPH-1 to -4, TRANSCEND-T2D-1 and Phase 2, with both estimands, kg and lb changes and the 104-week caveat.

• Retatrutide dose in units: mg-to-units conversion chart Units charts

  Convert retatrutide mg to U-100 units at 2.5, 3.333, 5, 10 and 20 mg/mL, with the formula, worked examples and the 2 to 12 mg trial steps in units.

Tirzepatide

FDA approved as Mounjaro (type 2 diabetes) and Zepbound (weight management, obstructive sleep apnea).

• Tirzepatide dosage chart: Zepbound and Mounjaro label doses Dosage charts

  Tirzepatide dosing chart from the FDA labels: 2.5 mg start, 2.5 mg steps every 4+ weeks to 15 mg, Zepbound maintenance doses, missed-dose rule and strengths.

• Mounjaro dosing schedule: what the FDA label says Dosing schedules

  The Mounjaro dosing schedule from the FDA label: 2.5 mg start, 2.5 mg steps after 4+ weeks, 15 mg adult and 10 mg pediatric maximums, and SURPASS-2 results.

• Zepbound dosing schedule: what the FDA label says Dosing schedules

  Zepbound dosing schedule from the FDA label: 2.5 mg start, 2.5 mg steps after 4+ weeks, maintenance by indication, the 15 mg maximum and missed doses.

• Tirzepatide half-life: how long it stays in your system Pharmacokinetics

  Tirzepatide half-life is about 5 days (Zepbound label: 5–6 days). See the decay formula, the fraction left by day, steady state at 4 weeks and washout times.

• Tirzepatide reconstitution chart: vial × water → units Reconstitution charts

  Tirzepatide reconstitution chart: mg/mL and U-100 units for 10–60 mg vials in 1–3 mL, a 30 mg example, and why FDA-approved vials need no mixing.

• Mounjaro savings card: eligibility, price and self-pay (2026) Savings and cost

  Mounjaro savings card terms as shown Oct 19, 2026: $25 covered fills, $499 when not covered, monthly and yearly caps, and the $499 LillyDirect self-pay price.

• Zepbound savings card: eligibility, price and LillyDirect self-pay (2026) Savings and cost

  Zepbound savings card eligibility and prices as shown Oct 19, 2026: $25 covered fills, $499 not covered, KwikPen card, LillyDirect self-pay and GoodRx facts.

• Tirzepatide side effects: trial rates by dose from the FDA labels Side effects

  Zepbound and Mounjaro side-effect rates by dose from the FDA labels: nausea, diarrhea, hair loss (7.1% of women vs 0.5% of men) and the boxed warning.

• Tirzepatide dose in units: mg-to-units conversion chart Units charts

  Convert tirzepatide mg to U-100 units at 5 to 30 mg/mL, with the formula, a 2.5 mg example, the 2.4 mg question, and how the FDA labels measure doses in mL.

• Zepbound injection sites: what the label and instructions say Using the label

  Zepbound injection sites per the FDA label: abdomen, thigh or back of upper arm, rotation, the KwikPen 2-inch rule, site reactions and storage by presentation.

Semaglutide

FDA approved as Ozempic (type 2 diabetes) and Wegovy (weight management, cardiovascular risk reduction).

• Semaglutide dosage chart: Wegovy and Ozempic label doses Dosage charts

  Wegovy and Ozempic dosage charts from the FDA labels: every titration step by week, the Wegovy pill ladder, 7.2 mg Wegovy HD, missed-dose rules and pens.

• Ozempic dosing schedule: the dose chart from the FDA label Dosing schedules

  Ozempic dosing schedule from the FDA label: 0.25 mg start, 0.5, 1 and 2 mg steps of 4+ weeks, which pen gives each dose, missed doses and 56-day storage.

• Wegovy dosing schedule: the dose chart from the FDA label Dosing schedules

  Wegovy dosing schedule and dose chart from the FDA label (revised 6/2026): weekly pen steps to 2.4 mg, the 7.2 mg HD option, the pill ladder and missed doses.

• Semaglutide half-life: how long it stays in your system Pharmacokinetics

  Semaglutide half-life is about 1 week per the FDA labels: how much remains day by day, time to steady state, and how long Wegovy and Ozempic stay in the body.

• Semaglutide reconstitution chart: vial × water → units Reconstitution charts

  Semaglutide reconstitution chart: mg/mL and U-100 units for 2, 5, 10 and 20 mg vials with 1–3 mL water, and why Wegovy and Ozempic pens are never mixed.

• Ozempic savings card: eligibility, terms and price in 2026 Savings and cost

  Ozempic savings card terms ($25, $100 monthly cap, 48 months), NovoCare self-pay prices and Medicare rules, as shown on Novo Nordisk pages on Oct 19, 2026.

• Wegovy savings card: eligibility, terms and price in 2026 Savings and cost

  Wegovy savings card terms, NovoCare self-pay prices, list price and the Medicare $50 bridge, as shown on Novo Nordisk pages on Oct 19, 2026.

• Semaglutide side effects: trial rates by dose Side effects

  Semaglutide side effects from the FDA labels: Wegovy 2.4 mg and 7.2 mg vs placebo, Ozempic 0.5 mg and 1 mg rates, the boxed warning and the 2026 label change.

• Semaglutide dose in units: conversion chart Units charts

  Semaglutide units chart: every Wegovy and Ozempic label dose converted to U-100 syringe units at 1, 2, 2.5 and 5 mg/mL, with the formula and worked examples.

• Wegovy injection sites: what the label and instructions say Using the label

  Wegovy injection sites per the FDA label: abdomen, thigh or upper arm, rotation, the 2-inch belly-button rule, pen vs syringe vs FlexTouch, storage, disposal.

Foundayo (orforglipron)

Lilly’s once-daily GLP-1 pill, FDA-approved Apr 1, 2026 for weight management in adults.

• Foundayo dosing schedule: the dose chart from the FDA label Dosing schedules

  Foundayo (orforglipron) dosing schedule from the FDA label (revised 7/2026): the 0.8 mg start, 30-day steps to 17.2 mg, missed doses and interactions.

• Foundayo savings card: price, eligibility and LillyDirect self-pay (2026) Savings and cost

  Foundayo savings card terms and prices as shown Oct 21, 2026: $25 covered fills, LillyDirect self-pay from $149, the $649 list price and the Medicare Bridge.

Across compounds

• Missed a GLP-1 dose: what each FDA label says Dosing schedules

  Missed a GLP-1 dose? The FDA label rules side by side for Wegovy, Ozempic, Zepbound, Mounjaro and Foundayo: time windows, skips, restarts and day changes.

• GLP-1 plotter tools compared: features, models and limits Tools

  A neutral feature table of GLP-1 plotter and dose-tracking tools for retatrutide, tirzepatide and semaglutide, plus what a level plotter can and cannot show.